Terms: = Leukemia AND PPM1D, Wip1, 8493, ENSG00000170836, O15297, WIP1, PP2C-DELTA AND Treatment
16 results:
1. The crossroads of cancer therapies and clonal hematopoiesis.
Singh A; Balasubramanian S
Semin Hematol; 2024 Feb; 61(1):16-21. PubMed ID: 38403501
[TBL] [Abstract] [Full Text] [Related]
2. Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors.
Franch-Expósito S; Mehine M; Ptashkin RN; Bolton KL; Bandlamudi C; Srinivasan P; Zhang L; Goodell MA; Gedvilaite E; Menghrajani K; Sánchez-Vela P; Mandelker D; Comen E; Norton L; Benayed R; Gao T; Papaemmanuil E; Taylor B; Levine R; Offit K; Stadler Z; Berger MF; Zehir A
JCO Precis Oncol; 2023 Aug; 7():e2300070. PubMed ID: 37561983
[TBL] [Abstract] [Full Text] [Related]
3. ppm1d Knockdown Suppresses Cell Proliferation, Promotes Cell Apoptosis, and Activates p38 MAPK/p53 Signaling Pathway in Acute Myeloid leukemia.
Li B; Hu J; He D; Chen Q; Liu S; Zhu X; Yu M
Technol Cancer Res Treat; 2020; 19():1533033820942312. PubMed ID: 32691668
[TBL] [Abstract] [Full Text] [Related]
4. Potentiality of Protein phosphatase Mg
Yu M; Hu J; He D; Chen Q; Liu S; Zhu X; Li B
J Clin Lab Anal; 2020 May; 34(5):e23171. PubMed ID: 31901183
[TBL] [Abstract] [Full Text] [Related]
5. Clonal hematopoiesis: Pre-cancer PLUS.
Silver AJ; Jaiswal S
Adv Cancer Res; 2019; 141():85-128. PubMed ID: 30691686
[TBL] [Abstract] [Full Text] [Related]
6. ppm1d Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy.
Hsu JI; Dayaram T; Tovy A; De Braekeleer E; Jeong M; Wang F; Zhang J; Heffernan TP; Gera S; Kovacs JJ; Marszalek JR; Bristow C; Yan Y; Garcia-Manero G; Kantarjian H; Vassiliou G; Futreal PA; Donehower LA; Takahashi K; Goodell MA
Cell Stem Cell; 2018 Nov; 23(5):700-713.e6. PubMed ID: 30388424
[TBL] [Abstract] [Full Text] [Related]
7. wip1 phosphatase as a potential therapeutic target in neuroblastoma.
Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R
PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463
[TBL] [Abstract] [Full Text] [Related]
8. wip1 deficiency inhibits HTLV-1 Tax oncogenesis: novel therapeutic prospects for treatment of ATL?
Gillet N; Carpentier A; Barez PY; Willems L
Retrovirology; 2012 Dec; 9():115. PubMed ID: 23256570
[TBL] [Abstract] [Full Text] [Related]
9. wip1 and p53 contribute to HTLV-1 Tax-induced tumorigenesis.
Zane L; Yasunaga J; Mitagami Y; Yedavalli V; Tang SW; Chen CY; Ratner L; Lu X; Jeang KT
Retrovirology; 2012 Dec; 9():114. PubMed ID: 23256545
[TBL] [Abstract] [Full Text] [Related]
10. Imatinib induces H2AX phosphorylation and apoptosis in chronic myelogenous leukemia cells in vitro via caspase-3/Mst1 pathway.
Zhang YJ; Lu CR; Cao Y; Luo Y; Bao RF; Yan S; Xue M; Zhu F; Wang Z; Duan LN
Acta Pharmacol Sin; 2012 Apr; 33(4):551-7. PubMed ID: 22388075
[TBL] [Abstract] [Full Text] [Related]
11. p53 Regulates LIF expression in human medulloblastoma cells.
Baxter EW; Milner J
J Neurooncol; 2010 May; 97(3):373-82. PubMed ID: 19907922
[TBL] [Abstract] [Full Text] [Related]
12. Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.
López-Guerra M; Trigueros-Motos L; Molina-Arcas M; Villamor N; Casado FJ; Montserrat E; Campo E; Colomer D; Pastor-Anglada M
Haematologica; 2008 Dec; 93(12):1843-51. PubMed ID: 18945750
[TBL] [Abstract] [Full Text] [Related]
13. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic wip1 phosphatase.
Yoda A; Toyoshima K; Watanabe Y; Onishi N; Hazaka Y; Tsukuda Y; Tsukada J; Kondo T; Tanaka Y; Minami Y
J Biol Chem; 2008 Jul; 283(27):18969-79. PubMed ID: 18482988
[TBL] [Abstract] [Full Text] [Related]
14. A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy.
Fiegl M; Büchner T; Hiddemann W; Braess J
Ann Hematol; 2005 Apr; 84(4):227-31. PubMed ID: 15517268
[TBL] [Abstract] [Full Text] [Related]
15. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493).
Frankel LS; Ochs J; Shuster JJ; Dubowy R; Bowman WP; Hockenberry-Eaton M; Borowitz M; Carroll AJ; Steuber CP; Pullen DJ
J Pediatr Hematol Oncol; 1997; 19(1):35-42. PubMed ID: 9065717
[TBL] [Abstract] [Full Text] [Related]
16. [Acute lymphoblastic leukemia in infants--results of treatment according to infant leukemia protocol--POG 8493].
Sońta-Jakimczyk D; Armata J; Bogusławska-Jaworska J; Cyklis R; Chybicka A; Grześkowiak-Melanowska J; Radwańska U; Swiatły A; Wieczorek M
Acta Haematol Pol; 1993; 24(2):131-8. PubMed ID: 8372612
[TBL] [Abstract] [Full Text] [Related]
